Abstracts tagged "Systemic sclerosis"

Abstract Number: 2600 • 2019 ACR/ARP Annual Meeting
‘If You Don’t Use It, You Lose It’: Rehabilitation of Finger Dexterity and Ability to Perform Activities of Daily Living in Systemic Sclerosis
Elena Eusterwiemann¹, Marina Anderson ², Mark Robinson ¹ and Gabor Barton ¹, ¹Liverpool John Moores University, Liverpool, United Kingdom, ²Aintree University Hospital, Liverpool
Background/Purpose: Hand involvement due to increased skin thickness and skin collagen content is one of the first manifestations of systemic sclerosis (SSc) leading to a…
Abstract Number: 2750 • 2019 ACR/ARP Annual Meeting
Development and Preliminary Validation of a Novel Lung Ultrasound Interpretation Criteria for the Detection of Interstitial Lung Disease in Patients with Systemic Sclerosis
Robert Fairchild¹, Diana Yang ², Melody Chung ¹, Laurel Sharpless ¹, Shufeng Li ³ and Lorinda Chung ¹, ¹Stanford University, Palo Alto, CA, ²Santa Clara Valley Medical Center, Palo Alto, CA, ³Division of Immunology and Rheumatology, Department of Medicine, Stanford, Palo Alto, CA
Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of systemic sclerosis (SSc), and screening, characterization, and monitoring of disease activity are important for therapeutic…
Abstract Number: 708 • 2019 ACR/ARP Annual Meeting
Improvement and Stabilization of Lung Function in Patients with SSc-ILD Treated with Nintedanib vs Placebo in a Randomized, Placebo-Controlled Phase III Trial: Proportions of Patients with FVC Changes Using Cutoffs Previously Proposed to Define Minimally Clinically Important Differences
Yannick Allanore¹, Dinesh Khanna ², Elizabeth Volkmann ³, Christian Stock ⁴, Martina Gahlemann ⁵, Nils Schoof ⁶, Oliver Distler ⁷ and Toby Maher ⁸, ¹Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ²Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ⁴Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁵Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁷Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ⁸National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom
Background/Purpose: Mean change in forced vital capacity percent predicted (FVC %pred) is a common endpoint in the assessment of treatment-related outcomes in patients with interstitial…
Abstract Number: 735 • 2019 ACR/ARP Annual Meeting
The Relationship Between Gastrointestinal Symptoms and Severity and Whole Gut Transit in Patients with Systemic Sclerosis
Zsuzsanna McMahan* ¹, Ana Tucker*², Jamie Perin ³, Jay Pasricha ⁴, Harvey Ziessman ⁵, Antony Rosen ¹ and Frederick Wigley ¹, ¹Johns Hopkins University, Division of Rheumatology, Baltimore, ²Johns Hopkins Bayview Medical Center, Baltimore, MD, ³Johns Hopkins University School of Public Health, Department of International Health, Baltimore, ⁴Johns Hopkins University, Division of Gastroenterology, Baltimore, ⁵Johns Hopkins University, Division of Radiology, Baltimore
Background/Purpose: The gastrointestinal (GI) tract is the most commonly affected internal organ system in systemic sclerosis (SSc), resulting in significant morbidity and mortality. Several studies…
Abstract Number: 1048 • 2019 ACR/ARP Annual Meeting
Clonally Expanded CD4+ Cytotoxic T Cells, Endothelial Cell Apoptosis and the Pathogenesis of Early Systemic Sclerosis
Takashi Maehara ¹, Cory Perugino², Naoki Kaneko ¹, Hamid Mattoo ³, Jesper Kers ⁴, Hugues Allard-Chamard ⁵, Vinay Mahajan ⁵, Hang Liu ⁵, Samuel Murphy ⁵, Musie Ghebremichael ⁵, Yesim Tuncay ⁵, Emanuel Della Torre ⁶, Lloyd Liang ², Sydney Montesi ⁷, Zachary Wallace ², David Fox ⁸, Robert Lafyatis ⁹, John Stone ¹⁰, Dinesh Khanna ¹¹ and Shiv Pillai ¹², ¹Kyushu University, Fukuoka, Japan, ²Massachusetts General Hospital, Boston, ³Sanofi, Cambridge, ⁴University of Amsterdam, Amsterdam, Netherlands, ⁵Ragon Institute of MGH, MTI and Harvard, Cambridge, ⁶Hospital San Raffaele, milan, Italy, ⁷Massachusetts General Hospital, Boston, MA, ⁸University of Michigan, Ann Arbor, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹¹Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ¹²Ragon Institude of MGH, MIT and Harvard, Charlestown, MA
Background/Purpose: The CD4+ T cell subset driving the pathogenesis of systemic sclerosis (SSc) remains poorly understood. Many different CD4+ T cell subsets have been implicated,…
Abstract Number: 1632 • 2019 ACR/ARP Annual Meeting
Evidence-based Consensus Statements for the Identification and Management of Interstitial Lung Disease in Systemic Sclerosis
Anna-Maria Hoffmann-Vold¹, Toby M. Maher ², Edward E. Philpot ³, Ali Ashrafzadeh ⁴ and Oliver Distler ⁵, ¹Dept. of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ²National Heart and Lung Institute, Imperial College London; Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK, London, United Kingdom, ³Respiratory Center of Excellence, IQVIA, Durham, NC, USA, Durham, NC, ⁴Rheumatology Center of Excellence, IQVIA, San Diego, CA, USA, San Diego, CA, ⁵Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: Guidelines are needed to aid early recognition and treatment of interstitial lung disease in systemic sclerosis (SSc-ILD). This study was conducted to develop expert…
Abstract Number: 1660 • 2019 ACR/ARP Annual Meeting
Serial Sublingual Videomicroscopy in Systemic Sclerosis Clinic: Are the Microcirculation Measurements Correlated with Gastrointestinal Symptoms?
Tracy Frech¹, Guo Wei ² and Maureen Murtaugh ³, ¹Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³University of Utah and Salt Lake VAMC, Salt Lake City
Background/Purpose: Intravital microscopy of the sublingual microcirculation provides estimates of perfused barrier region (PBR) and red blood cell fraction (RBCfract), which quantifies vasculopathy and, similar…
Abstract Number: 2601 • 2019 ACR/ARP Annual Meeting
Trabecular Bone Score and Malnutrition in a Cohort of Systemic Sclerosis Patients
Massimo Patane' ¹, Sabrina Paolino ¹, Veronica Tomatis ², Andrea Casabella ³, Carmen Pizzorni ¹, Luca Carmisciano ⁴, Alessio Signori ⁴ and Maurizio Cutolo⁵, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS Polyclinic Hospital San Martino, University of Genoa, Genoa, Italy.2Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy, genova, Liguria, Italy, ³1 Research Laboratory and Academic Division of the Clinical Rheumatology Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁴Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy, ⁵Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease characterized by microvascular damage, immune system activation and progressive fibrosis of the skin and internal organs.…
Abstract Number: 2913 • 2019 ACR/ARP Annual Meeting
Serum Interferon Score Predicts Clinical Outcome at 12 Months in Diffuse Cutaneous Systemic Sclerosis as Measured by Global Ranked Composite Score (GRCS) and Composite Response Index in SSc (CRISS)
Antonio Carriero ¹, Giuseppina Abignano ², MIchelle Hutchinson ³, Karri Ballard ⁴ and Francesco Del Galdo⁵, ¹University of Leeds, Leeds, England, United Kingdom, ²3Rheumatology Institute of Lucania (IReL) and University of Leeds, Leeds, United Kingdom, ³University of Leeds and LTHT NIHR Biomedical Research Centre, Leeds, England, United Kingdom, ⁴Myriad RBM, austin, TX, ⁵University of Leeds and LTHT NIHR Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is a highly heterogeneous disease orphan of effective disease modifying agents. The diffuse cutaneous clinical subset (dcSSc) is currently targeted in…
Abstract Number: 810 • 2018 ACR/ARHP Annual Meeting
Sexual Dysfunction in Women with Systemic Sclerosis
Marina Soledad Dalpiaz¹, Juan Argüello², Maria Florencia Rodriguez³, Marta Mamani⁴, Anastasia Secco⁵, Natalia Tamborenea², Eduardo Kerzberg⁶, Sandra Fabiana Montoya⁶, Carolina Aimo⁶, Fernando Manuel Villalobos⁶, Eliana Rebeca Serrano⁷, Maria Elena Crespo Espindola⁸ and Ana Lía Gervilla Galan⁹, ¹Hospital Bernardino Rivadavia, Ciudad Autónoma de Buenos Aires, Argentina, ²Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ³Reumatologia, Hospital Bernardino Rivadavia, Ciudad Autónoma de Buenos Aires, Argentina, ⁴Rheumatology Department, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ⁵Rheumatology Section, Hospital Bernardino Rivadavia, CABA, Argentina, ⁶Hospital General de Agudos José María Ramos Mejía, BUENOS AIRES, Argentina, ⁷Rheumatology Section, Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ⁸Reumatologia, Hospital Señor del Milagro, Salta, Argentina, ⁹Hospital San Roque, San Salvador de Jujuy, Argentina
Background/Purpose: Impaired sexual function is common among women with chronic illnesses, including Systemic Sclerosis (SSc). Studies of sexual functioning among women with SSc have concluded…
Abstract Number: 898 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Tocilizumab for the Treatment of Systemic Sclerosis: Results from a Phase 3 Randomized Controlled Trial
Dinesh Khanna¹, Celia J. F. Lin², Masataka Kuwana³, Yannick Allanore⁴, Anastas Batalov⁵, Irena Butrimiene⁶, Patricia Carreira⁷, Marco Matucci Cerinic⁸, Oliver Distler⁹, Dusanka Martinović Kaliterna¹⁰, Carina Mihai¹¹, Mette Mogensen¹², Marzena Olesinska¹³, Janet E. Pope¹⁴, Gabriela Riemekasten¹⁵, Tatiana S. Rodriguez-Reyna¹⁶, Maria José Santos¹⁷, Jacob van Laar¹⁸, Helen Spotswood¹⁹, Jeffrey Siegel², Angelika Jahreis², Daniel E. Furst²⁰ and Christopher P. Denton²¹, ¹University of Michigan, Ann Arbor, MI, ²Genentech, Inc., South San Francisco, CA, ³Nippon Medical School, Tokyo, Japan, ⁴Cochin Hospital, Paris Descartes University, Paris, France, Paris, France, ⁵Medical University of Plovdiv, Plovdiv, Bulgaria, ⁶Rheumatology Clinic, Medical Faculty, Vilnius University, Vilnius, Lithuania, ⁷Servicio de Reumatología, Hospital Universitario, Madrid, Spain, ⁸University of Florence, Florence, Italy, ⁹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ¹⁰University of Split, Split, Croatia, ¹¹Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ¹²Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark, ¹³National Institute of Geriatrics, Rheumatology and Rehabilitation,, Warsaw, Poland, ¹⁴Department of Medicine, University of Western Ontario, London, ON, Canada, ¹⁵Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany, ¹⁶Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ¹⁷Serviço de Reumatologia do Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, ¹⁸University Medical Center Utrecht, Utrecht, Netherlands, ¹⁹Roche Products Ltd., Welwyn Garden City, United Kingdom, ²⁰University of California Los Angeles, Los Angeles, CA, ²¹University College London, London, United Kingdom
Background/Purpose: The anti–interleukin-6 (IL-6) receptor-alpha antibody tocilizumab (TCZ) demonstrated numeric improvement in skin thickening (modified Rodnan skin score [mRSS]) and clinically meaningful lung function preservation…
Abstract Number: 1212 • 2018 ACR/ARHP Annual Meeting
Superiority of Musculoskeletal Ultrasound (MSUS) over Clinical Examination Regarding Detection of Arthritis in Patients with Systemic Sclerosis
Daria Feldmann¹, Reinhard Voll², Florian Kollert³ and Stephanie Finzel¹, ¹Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ²Clinic for Rheumatology and Clinical Immunology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ³Department of Rheumatology, Immunology, and Allergology, Inselspital, University Hospital Bern, Bern, Switzerland
Background/Purpose: Arthralgia is frequent in patients with systemic sclerosis (SSc). However, correct clinical assessment of arthritis remains a challenge especially in patients with severe soft…
Abstract Number: 1726 • 2018 ACR/ARHP Annual Meeting
Sexual Dysfunction in Systemic Sclerosis Female Patients
Barbora Hermankova^1,2, Maja Spiritovic^1,2, Hana Smucrova², Sabina Oreska^2,3, Hana Storkanova^2,3, Karel Pavelka^3,4, Jiri Vencovsky^2,5, Ladislav Šenolt^2,3, Radim Becvar^2,3 and Michal Tomcik^2,3, ¹Department of Physiotherapy, Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ³Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵Department Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease leading to various physical and psychological impairments including sexual dysfunction. The aim of this study was…
Abstract Number: 1738 • 2018 ACR/ARHP Annual Meeting
Detect Outperforms Echocardiography Based Screening Guidelines for Early Detection of Systemic Sclerosis Associated Pulmonary Arterial Hypertension
Amber Young¹, Victor M. Moles^2,3, Vivek Nagaraja¹, Dharshan Vummidi⁴, Scott H. Visovatti³, Vallerie McLaughlin³ and Dinesh Khanna¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²Hospital Jose Maria Cullen, Santa Fe, Argentina, ³Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ⁴Department of Radiology, University of Michigan, Ann Arbor, MI
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of mortality in patients with systemic sclerosis (SSc). Active screening can detect SSc-PAH earlier and may…
Abstract Number: 1900 • 2018 ACR/ARHP Annual Meeting
FGFR3/ FGF9 Regulates the Activity of Profibrotic Cytokine and Growth Factor Pathways to Drive Fibroblast Activation and Tissue Fibrosis in Systemic Sclerosis
Debomita Chakraborty¹, Lena Summa², Thuong Trinh-Minh³, Chih-Wei Chen³, Alina Soare², Andreas Ramming⁴, Oliver Distler⁵, Georg Schett² and Jörg Distler³, ¹Department of Internal Medicine 3- Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁴Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁵Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Fibroblast growth factor receptor3 (FGFR3) is a member of the family of 4 different receptors (FGFR1-4) with more than 23 identified ligands FGF1-23. Each…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.